Trials
8 active
16 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants will receive felzartamab by intravenous infusion.”In the company’s words, NCT06685757 on ClinicalTrials.gov
- Tested for
- Antibody-mediated Rejection (2 trials), Microvascular Inflammation (2 trials), Immunoglobulin A Nephropathy (IgAN), Primary Membranous Nephropathy, Graves' Disease, Immunoglobulin A Nephropathy, Generalized Myasthenia Gravis
- Main trialPhase 3
- “In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney. Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In…”In the company’s words, NCT06685757 on ClinicalTrials.gov
- Other names
- MOR202 · TJ202 · BIIB148 · MOR03087 · HIB202
Other drugs for Immunoglobulin A Nephropathy (IgAN)
Coming up8
- 1 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2028Phase 2 trial completes · ClinicalTrials.gov
- 10 Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- 13 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
- 19 Sep 2028Phase 2 trial completes · ClinicalTrials.gov
- 28 Jan 2030Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07939802
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Dec 2026 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | |
| Phase 3Recruiting | 31 May 2027 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | |
| Phase 3Recruiting | 28 Jan 2030 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | |
| Phase 3Enrolling by invitation | 31 Dec 2031 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) | |
| Phase 2Recruiting | 31 Jan 2028 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old | |
| Phase 2Recruiting | 10 Feb 2028 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation | |
| Phase 2Not yet recruiting | 13 Aug 2028 | A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) | |
| Phase 2Not yet recruiting | 19 Sep 2028 | A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old | |
| Phase 3Completed | 30 Jun 2024 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Completed | 28 Jan 2023 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Completed | 6 Feb 2023 | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | |
| Phase 2Completed | 14 Dec 2023 | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | |
| Phase 1/2Completed | 19 Jan 2022 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | |
| Phase 1Terminated | 14 Dec 2022 | A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus | |
| Phase 1Completed | 24 Jun 2026 | A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old | |
| Phase 2Ended | not given | Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026